Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1

Ge, Daniel Tianfang; Law, Pui Ying Peggy; Kong, Siu‐Kai; Ho, Yu‐Ling

doi:10.1016/j.toxlet.2008.10.017

Cited by 8 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 In addition, some recent findings imply that disturbed cellular glucose transport and GLUT1 function may underlie the dysglycemic effects of ciprofloxacin and levofloxacin. 21 This adverse effect has important clinical implications, especially for diabetic patients. 22 …”

Section: Introductionmentioning

confidence: 99%

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia

Kabbara¹,

Ramadan²,

Rahbany³

et al. 2015

TCRM

View full text Add to dashboard Cite

BackgroundFluoroquinolones are among the most widely prescribed antibiotics. However, concerns about increasing resistant microorganisms and the risk of dysglycemia associated with the use of these agents have emerged.ObjectiveThe primary objective of the study was to evaluate the appropriate use of commonly prescribed fluoroquinolones, including appropriate indication, dose, dose adjustment in renal impairment, and duration of treatment. The secondary objective was to investigate the dysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabetic and nondiabetic patients.MethodsA prospective observational study at a teaching hospital in Lebanon was conducted over a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones (levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruited from internal medicine floors and intensive care units.ResultsThe final percentage for the appropriate indication, dose, and duration of fluoroquinolone therapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patients did not receive the appropriate dose adjustment according to their level of renal impairment. In addition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was more frequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxifloxacin (7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The highest incidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin (39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacin group, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%).ConclusionThe major clinical interventions for the future will adjust the dose and duration of therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia was less common than hyperglycemia.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia

Kabbara¹,

Ramadan²,

Rahbany³

et al. 2015

TCRM

View full text Add to dashboard Cite

show abstract

“…Thus it plays a crucial role in the regulation of GLUT1 mRNA stability. This was evidenced by a recent study, where it was also demonstrated that the gatifl oxacin decreases the mRNA levels of the GLUT1 gene (Ge et al, 2009). However, the molecular mechanism of gatifl oxacin induced GLUT1 mRNA degradation was not been established so far.…”

Section: Resultsmentioning

confidence: 97%

“…In animal studies, gatifloxacin has been shown to increase epinephrine release when given in higher doses, thus increasing the metabolic rate leading to hypoglyc-emic condition (Ishiwata et al, 2006). In contrast, chronic hyperglycemic effect could be due to the down regulation of glucose transporter 1 (GLUT1) expression in presence of gatifloxacin (Ge et al, 2007(Ge et al, , 2009. Interestingly, in the same study, it was also demonstrated that the gatifloxacin increases the GLUT1 promoter activity and decreases the mRNA levels of the gene suggesting that the drug affects the stability of the GLUT1 mRNA by a mechanism yet to be understood.…”

Section: Introductionmentioning

confidence: 99%

Comparative and chemical proteomic approaches reveal gatifloxacin deregulates enzymes involved in glucose metabolism

et al. 2011

View full text Add to dashboard Cite

Gatifloxacin has been associated with increased risks of hypoglycemic and hyperglycemic side effects. In order to understand the molecular mechanism of gatifloxacin induced deregulation of glucose metabolism, a combination of comparative and chemical proteomic approaches were employed using yeast as a model system. Differential protein expression studies using two dimensional electrophoresis and mass spectrometry reveal that gatifloxacin deregulates the expression of key enzymes involved in glucose metabolism. Furthermore, affinity chromatography and LC-MS(E) analysis led to identification of enolase, as one of the key gatifloxacin binding proteins. Fluorescence spectrometric studies confirmed that the gatifloxacin indeed binds to enolase. Role of enolase in regulation of gatifloxacin induced dysglycemic effect is discussed.

show abstract

“…Animal studies show that the mechanism of fluoroquinolone induced hypoglycemia is to promote insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta cells [8,9]. According to clinical research, levofloxacin and ciprofloxacin may contribute to aberrant blood glucose levels by impairing cells' GLUT1 and glucose transport mechanisms [10]. Also, gatifloxacin can also trigger the vacuolation of pancreatic beta cells, leading to reduced insulin levels and hyperglycemia.…”

Section: Discussionmentioning

confidence: 99%

Possible sitafloxacin-induced dysglycemia: Case report

Mengqi¹,

Zhu²,

Huang³

et al. 2022

J Clin Images Med Case Rep

View full text Add to dashboard Cite

A 93-year-old diabetic patient was prescribed sitafloxacin (100 mg, bid, po) for 8 days to treat a pulmonary infection. Prior to the treatment with sitafloxacin, his blood sugar was well controlled, but during treatment, his blood sugar showed abnormal biphasic dysregulation, with a downward trend in the early stages of treatment (d1-3) and an upward trend in the late stages of treatment (d4-8), and the dysglycemia persisted for about 20 days after treatment. Sitafloxacin, like other fluoroquinolones, may be strongly linked to glucose homeostasis abnormalities in this case, necessitating clinical medical staff vigilance, particularly in patients with high-risk diabetes.

show abstract

Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1

Cited by 8 publications

References 26 publications

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia

Comparative and chemical proteomic approaches reveal gatifloxacin deregulates enzymes involved in glucose metabolism

Possible sitafloxacin-induced dysglycemia: Case report

Contact Info

Product

Resources

About

Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1

Cited by 8 publications

References 26 publications

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of&nbsp;dysglycemia

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of&nbsp;dysglycemia

Comparative and chemical proteomic approaches reveal gatifloxacin deregulates enzymes involved in glucose metabolism

Possible sitafloxacin-induced dysglycemia: Case report

Contact Info

Product

Resources

About

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia